Mesoblast (MESO) Competitors $13.52 +0.64 (+4.97%) Closing price 04:00 PM EasternExtended Trading$13.54 +0.02 (+0.15%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MESO vs. GRFS, RVMD, RYTM, LEGN, RNA, AXSM, ABVX, NUVL, MRUS, and CRSPShould you be buying Mesoblast stock or one of its competitors? The main competitors of Mesoblast include Grifols (GRFS), Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Avidity Biosciences (RNA), Axsome Therapeutics (AXSM), Abivax (ABVX), Nuvalent (NUVL), Merus (MRUS), and CRISPR Therapeutics (CRSP). These companies are all part of the "pharmaceutical products" industry. Mesoblast vs. Its Competitors Grifols Revolution Medicines Rhythm Pharmaceuticals Legend Biotech Avidity Biosciences Axsome Therapeutics Abivax Nuvalent Merus CRISPR Therapeutics Mesoblast (NASDAQ:MESO) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk. Do insiders & institutionals hold more shares of MESO or GRFS? 1.4% of Mesoblast shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer MESO or GRFS? In the previous week, Mesoblast had 8 more articles in the media than Grifols. MarketBeat recorded 10 mentions for Mesoblast and 2 mentions for Grifols. Grifols' average media sentiment score of 1.41 beat Mesoblast's score of 0.19 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 1 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Grifols 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, MESO or GRFS? Mesoblast has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.64, meaning that its share price is 36% less volatile than the S&P 500. Is MESO or GRFS more profitable? Company Net Margins Return on Equity Return on Assets MesoblastN/A N/A N/A Grifols N/A N/A N/A Which has stronger earnings and valuation, MESO or GRFS? Grifols has higher revenue and earnings than Mesoblast. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMesoblast$5.90M293.32-$87.96MN/AN/AGrifols$7.81B0.87$169.80M$1.178.46 Do analysts prefer MESO or GRFS? Mesoblast currently has a consensus target price of $18.00, suggesting a potential upside of 33.14%. Grifols has a consensus target price of $10.30, suggesting a potential upside of 4.04%. Given Mesoblast's stronger consensus rating and higher probable upside, analysts clearly believe Mesoblast is more favorable than Grifols.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.20Grifols 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.60 SummaryMesoblast beats Grifols on 9 of the 12 factors compared between the two stocks. Get Mesoblast News Delivered to You Automatically Sign up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MESO vs. The Competition Export to ExcelMetricMesoblastMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.73B$3.12B$5.76B$9.91BDividend YieldN/A2.28%6.66%4.49%P/E RatioN/A21.0283.0126.65Price / Sales293.32379.56503.03163.66Price / CashN/A43.5325.7028.92Price / Book3.218.1210.796.52Net Income-$87.96M-$53.35M$3.29B$266.21M7 Day Performance-15.24%0.05%0.02%-0.76%1 Month Performance-12.38%7.08%7.06%3.83%1 Year Performance106.41%11.92%50.09%24.39% Mesoblast Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MESOMesoblast2.2069 of 5 stars$13.52+5.0%$18.00+33.1%+85.3%$1.73B$5.90M0.0080News CoverageGRFSGrifols3.9231 of 5 stars$9.82-3.3%$10.30+4.9%+2.2%$6.99B$7.81B8.3923,822Positive NewsGap UpRVMDRevolution Medicines4.4891 of 5 stars$35.67-3.6%$69.92+96.0%-4.3%$6.92BN/A-7.93250Positive NewsRYTMRhythm Pharmaceuticals3.3217 of 5 stars$99.20-3.9%$101.57+2.4%+121.3%$6.86B$130.13M0.00140News CoveragePositive NewsLEGNLegend Biotech3.527 of 5 stars$34.60-2.7%$73.00+111.0%-37.3%$6.53B$627.24M0.002,609RNAAvidity Biosciences3.2021 of 5 stars$45.27-2.3%$67.00+48.0%+16.1%$5.96B$10.90M-12.72190Positive NewsAXSMAxsome Therapeutics4.7788 of 5 stars$116.31-1.9%$178.00+53.0%+36.1%$5.91B$385.69M0.00380News CoveragePositive NewsAnalyst ForecastInsider TradeABVXAbivax2.4558 of 5 stars$77.46+0.2%$92.33+19.2%+574.1%$5.84BN/A0.0061News CoveragePositive NewsShort Interest ↓NUVLNuvalent3.2446 of 5 stars$74.05-2.7%$118.91+60.6%-4.9%$5.49BN/A0.0040News CoveragePositive NewsAnalyst ForecastMRUSMerus3.0251 of 5 stars$65.74-2.6%$88.64+34.8%+32.0%$5.10B$36.13M0.0037News CoveragePositive NewsCRSPCRISPR Therapeutics3.5886 of 5 stars$54.13-0.3%$71.60+32.3%+16.4%$4.94B$37.31M0.00460Positive NewsAnalyst Revision Related Companies and Tools Related Companies GRFS Competitors RVMD Competitors RYTM Competitors LEGN Competitors RNA Competitors AXSM Competitors ABVX Competitors NUVL Competitors MRUS Competitors CRSP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MESO) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersMusk Warns. Trump Acts. Your Retirement May Depend on ItWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThis Coin Could Explode, and it’s Hiding in Plain Sight!The #1 coin with skyrocket potential right now... Sometimes the biggest opportunities are hiding in plain s...Crypto 101 Media | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mesoblast Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Mesoblast With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
